Your shopping cart is empty

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Pharmacyclics Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial

FDAnews Drug Daily Bulletin

Oct. 16, 2012 | Vol. 9 No. 203

Pharmacyclics Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial

Pharmacyclics announced the international, randomized Phase III clinical trial of ibrutinib (PCI-32765) in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma has enrolled its fifth patient.
The Sacramento Bee

Register Now
Print This Page
Email This Article
RSS
Archives

Mylan Launches Generic Tricor Tablets Is the FDA Approving too Many Drugs Starting with X and Z?Court Rejects Merck Deal Over Vioxx Citizens in Poor EU States Can’t Afford Medicines, Health Promoters Say

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.